In PRISM3, a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, researchers assessed an investigational oral microbiome drug CP101 in 206 patients with recurrent C. difficle at 51 sites across the United States and Canada.

The drug did meet the primary endpoint of sustained clinical cure among 74.5% of the patients with recurrent C. difficile who received a single administration.  By comparison, 61.5% of control patients who received standard-of-care antibiotic therapy alone met the primary efficacy endpoint (P < .05).

Jessica Allegretti, MD, MPH, was the principal investigator in the PRISM3 clinical trial at Brigham and Women’s hospital in Boston. The press release was made by Finch Therapeutics.

See the review article on Healio here.